Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Henan Lingrui Pharmaceutical CoSHSE:600285 -1.17%85 ROC (Joel Greenblatt) % is 169.47% as of Mar. 2026, which is 203% above its 10-year median of 55.96. GuruFocus rates SHSE:600285 with a GF Score™ of 85/100 and a GF Value™ of ¥24.55 (Fairly Valued). The stock has 2 warning signs investors should review. Among 983 Drug Manufacturers companies, Henan Lingrui Pharmaceutical Co ranks better than 95.22% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Henan Lingrui Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 169.47%.
The historical rank and industry rank for Henan Lingrui Pharmaceutical Co's ROC (Joel Greenblatt) % or its related term are showing as below:
SHSE:600285'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 28.07 Med: 55.96 Max: 134.47
Current: 132.12
During the past 13 years, Henan Lingrui Pharmaceutical Co's highest ROC (Joel Greenblatt) % was 134.47%. The lowest was 28.07%. And the median was 55.96%.
SHSE:600285's ROC (Joel Greenblatt) % is ranked better than 95.22% of 983
companies
in the Drug Manufacturers industry
Industry Median: 11.44
vs SHSE:600285: 132.12
Henan Lingrui Pharmaceutical Co (SHSE:600285) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Lingrui Pharmaceutical Co ROC (Joel Greenblatt) % Chart
SHSE:600285 vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Henan Lingrui Pharmaceutical Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Henan Lingrui Pharmaceutical Co ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Henan Lingrui Pharmaceutical Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Henan Lingrui Pharmaceutical Co's ROC (Joel Greenblatt) % falls into.
Henan Lingrui Pharmaceutical Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 169.47% mean?
Henan Lingrui Pharmaceutical Co (SHSE:600285) has a ROC (Joel Greenblatt) % of 169.47% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Henan Lingrui Pharmaceutical Co and its competitors. This is 203% above median its historical median of 55.96. Over the past decade, Henan Lingrui Pharmaceutical Co's ROC (Joel Greenblatt) % has ranged from 28.07 to 134.47. According to the industry distribution chart, Henan Lingrui Pharmaceutical Co ranks #47 out of 983 companies in the Drug Manufacturers industry, placing it in the top 4.8%.
Is Henan Lingrui Pharmaceutical Co's ROC (Joel Greenblatt) % too high?
Henan Lingrui Pharmaceutical Co's current ROC (Joel Greenblatt) % of 169.47% is 203% above median its 10-year median of 55.96. Over the past 10 years, this metric has ranged from a low of 28.07 to a high of 134.47. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.44. Henan Lingrui Pharmaceutical Co's value of 169.47% is 1381.4% above this industry median. Based on the distribution chart, Henan Lingrui Pharmaceutical Co ranks #47 out of 983 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Henan Lingrui Pharmaceutical Co has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Henan Lingrui Pharmaceutical Co's ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Henan Lingrui Pharmaceutical Co ranks #47 out of 983 companies for ROC (Joel Greenblatt) %. This places Henan Lingrui Pharmaceutical Co in the top 5% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.44. Henan Lingrui Pharmaceutical Co's value of 169.47% is 1381.4% above this benchmark. Historically, Henan Lingrui Pharmaceutical Co's own ROC (Joel Greenblatt) % has ranged from 28.07 to 134.47 over the past decade. While the company's 10-year median is 55.96 vs. the industry median of 11.44, Henan Lingrui Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.44, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Henan Lingrui Pharmaceutical Co's current ROC (Joel Greenblatt) % of 169.47% is 1381.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Henan Lingrui Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Henan Lingrui Pharmaceutical Co's current ROC (Joel Greenblatt) % is 169.47%, which is 203% above median its own 10-year median of 55.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Lingrui Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co (SHSE:600285) is currently considered Fairly Valued. The stock's GF Value™ is ¥24.55, compared to a current price of ¥22.82 — trading 7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 169.47%, which is 203% above median its 10-year median of 55.96 and 1381.4% above the Drug Manufacturers industry median of 11.44. Henan Lingrui Pharmaceutical Co's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Henan Lingrui Pharmaceutical Co (SHSE:600285), the current ROC (Joel Greenblatt) % is 169.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Henan Lingrui Pharmaceutical Co (SHSE:600285) Overvalued in 2026?
Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥22.82 is trading 7% below its estimated GF Value™ of ¥24.55.
GuruFocus considers Henan Lingrui Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600285:
ROC (Joel Greenblatt) %: 169.47% (203% above median its 10-year median of 55.96)
GF Value™: ¥24.55 vs. price of ¥22.82 (7% below fair value)
Industry Position: 1381.4% above the Drug Manufacturers median (#47 of 983)
No single metric tells the full story. See the SHSE:600285 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Henan Lingrui Pharmaceutical Co Ltd is a Chinese company engaged in the development, production, and distribution of pharmaceuticals. The Company's products include tablets, capsules, injections and other medicines.
85GF Score
Get the complete analysis for SHSE:600285
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600285 has been successfully added to your 
